Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Stephen W. Behrman, Al B. Benson, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian G. Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey M. Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle K. LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney L. Scaife, Jeanne Shen, Charles M. Vollmer, Robert A. Wolff, Brian M. Wolpin, Beth Lynn, Giby V. George
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.